within Pharmacolibrary.Drugs.ATC.L;

model L01EH02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.0036,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.36,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008833333333333334,
    Tlag           = 5.46,            
    Vdp             = 3.55,
    k12             = 1720,
    k21             = 1720
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EH02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Neratinib is an oral, irreversible tyrosine kinase inhibitor targeting HER2 and EGFR receptors. It is primarily used for the extended adjuvant treatment of early-stage HER2-positive breast cancer and is an FDA-approved medication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in cancer patients (mainly women, adults) after oral administration; parameters represent typical values from published clinical pharmacology studies.</p><h4>References</h4><ol><li><p>Abbas, R, et al., &amp; Sonnichsen, D (2011). Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. <i>British journal of clinical pharmacology</i> 71(4) 522–527. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2010.03845.x&quot;>10.1111/j.1365-2125.2010.03845.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21395644/&quot;>https://pubmed.ncbi.nlm.nih.gov/21395644</a></p></li><li><p>Mahajan, R, et al., &amp; Khan, MS (2023). Optimization of a HPLC-UV bioanalytical method using Box-Behnken design to determine the oral pharmacokinetics of neratinib maleate in Wistar rats. <i>Biomedical chromatography : BMC</i> 37(11) e5731–None. DOI:<a href=&quot;https://doi.org/10.1002/bmc.5731&quot;>10.1002/bmc.5731</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37651999/&quot;>https://pubmed.ncbi.nlm.nih.gov/37651999</a></p></li><li><p>Keyvanjah, K, et al., &amp; Wong, A (2019). Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. <i>Cancer chemotherapy and pharmacology</i> 84(5) 1125–1132. DOI:<a href=&quot;https://doi.org/10.1007/s00280-019-03951-x&quot;>10.1007/s00280-019-03951-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31512028/&quot;>https://pubmed.ncbi.nlm.nih.gov/31512028</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EH02;
